Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropane SCHEMBL27365076 | 0.94 | TSHR (0.48) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL16707218 | 0.86 | TSHR (0.58) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL14148186 | 0.85 | TSHR (0.56) | TSHRALDH1A1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL7741371 | 0.81 | LMNA (0.52) | TSHRALDH1A1LMNAKDM4EHSD17B10 | |
| SCHEMBL13502946 | 0.81 | ALDH1A1 (0.40) | TSHRALDH1A1KMT2ALMNA | |
| SCHEMBL19821796 | 0.80 | TSHR (0.48) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL17909484 | 0.80 | TSHR (0.50) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL17909221 | 0.80 | TSHR (0.50) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL21512465 | 0.80 | KMT2A (0.47) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL24800795 | 0.79 | TSHR (0.52) | TSHRALDH1A1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6415614-B1 | CONTROLLING VAPOR PRESSURE OF MIXTURE | VISTEON GLOBAL TECHNOLOGIES, INC. | 2002-07-09 | — | — | US | claimed |
| US-9801851-B2 | Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150133462-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BCR-ABL POSITIVE LYMPHOBLASTIC LEUKEMIAS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-05-14 | — | — | US | disclosed |
| CN-100522944-C | Carboxylic acid derivatives and salts thereof | EISAI CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| CN-1503774-A | Carboxylic acid derivatives and salts thereof | ������������ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| CN-1058781-A | New heterocyclic anthracycline hydrocarbon homologue | IAF BIOCHEM INT (CA) | 1992-02-19 | — | — | CN | disclosed |
| US-4978754-A | REACTING B-ALKOXY-SUBSTITUTED CARBOXYLATE WITH CYCLIC AMINE, REMOVING ALCOHOL IN PRESENCE OF BASIC CATALYST | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1990-12-18 | — | — | US | disclosed |
| EP-0321256-A2 | Process of preparing unsaturated carboxylic acid amides | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133462-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BCR-ABL POSITIVE LYMPHOBLASTIC LEUKEMIAS | ABL1, BCR, ABL2 | TSHR 4621/4885ALDH1A1 2348/4885KMT2A 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.